A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma-Reference-Cited by-同舟云学术

A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma

Published:2022-09-30 Issue:2 Volume:12 Page:152-158
ISSN:2192-4449
Container-title:CEN Case Reports
language:en
Short-container-title:CEN Case Rep

Author:

Morita Daisuke,Ito Kenji^ORCID,Ikeuchi Nobumitsu,Nishida Yoshihiro,Igata Fumiyasu,Nakamura Tsubasa,Murayama Hiroyuki,Watanabe Maho,Takahashi Koji,Yasuno Tetsuhiko,Uesugi Noriko,Fujita Masaki,Oda Takashi,Masutani Kosuke

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://link.springer.com/content/pdf/10.1007/s13730-022-00737-8.pdf

Reference25 articles.

1. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

2. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26:5589–95.

3. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up. Ann Oncol. 2018;29:iv192–237.

4. Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS SSO and TOS. Ann Oncol. 2019;30:171–210.

5. Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–89.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Afatinib;Reactions Weekly;2023-05-20